Images List Premium Download Classic

Erythropoietin

Erythropoietin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods of treating cognitive impairment
University Of South Florida
July 06, 2017 - N°20170189490

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible ...
Compositions and methods of preventing erythropoietin associated hypertension
University Of South Florida
June 22, 2017 - N°20170173150

The invention also provides a method of reducing hypertension in a mammal receiving epo, and pharmaceutical compositions containing a soluble epo-bp and/or a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor.
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Derivatisation of erythropoietin (epo)
Lipoxen Technologies Limited
May 04, 2017 - N°20170119893

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
Use of negative functional modulators of erythropoietin for therapy
Andremacon S.r.l.
April 27, 2017 - N°20170114132

The invention relates to negative functional modulators of erythropoietin (epo) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia a and b, von willebrand disease, angiodysplasia, proliferative disorders and neurological diseases ...
Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
Novagen Holding Corporation
April 27, 2017 - N°20170114110

A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic ...
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrameric cytokines with improved biological activity
Ibc Pharmaceuticals, Inc.
March 02, 2017 - N°20170056516

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety. The ddd moieties form dimers that bind to the ad moieties, resulting in a 2:1 ratio ...
Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
Remedor Biomed Ltd.
March 02, 2017 - N°20170056480

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or ...
Novel nitrogen-containing heteroaryl compounds and methods of use thereof
Fibrogen, Inc.
February 09, 2017 - N°20170035747

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
Compounds that bind to the erythropoietin receptor
Epodose Llc
February 02, 2017 - N°20170029481

The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin.
New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency ...
Epodose Llc
February 02, 2017 - N°20170027970

Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.
Anti-erythropoietin antibodies
Amgen Inc.
January 19, 2017 - N°20170015743

The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.
Method for purifying pegylated erythropoietin
Hoffmann-la Roche Inc.
January 12, 2017 - N°20170008941

Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a ...
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Purification of erythropoietin
F. Hoffmann-la Roche Ag
November 17, 2016 - N°20160333066

In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing calcium-ions and namely under conditions under which the ...
Vectors conditionally expressing protein
Intrexon Corporation
November 03, 2016 - N°20160317678

This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the ...
Conjugate comprising erythropoietin and a branched polymer structure
Centro De Inmunologia Molecular
November 03, 2016 - N°20160317674

The present invention discloses a conjugate comprising erythropoietin (epo) and an asymmetric branched polymeric structure comprising two branches of monomethoxypolyethylene glycol (mpeg), where the molecular mass of one of these mpeg branches is between 10 kda and 14 kda, and the molecular mass of the other branch of mpeg is between 17 kda and 23 kda, as well as the pharmaceutical compositions containing it. ...
Pharmaceutical composition comprising erythropoietin and ceftriaxone and a method for treating parkinson's disease dementia
Raygene Biotech International Inc.
October 27, 2016 - N°20160310571

The invention discloses a pharmaceutical composition for treating parkinson's disease dementia (pdd), which including erythropoietin and ceftriaxone. The invention also discloses a use of the pharmaceutical composition in the manufacture of a medicament for the treatment of pdd.
Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides
Raygene Biotech International Inc.
October 20, 2016 - N°20160303195

The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (epo)-derived oligopeptides.
Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
Rockwell Medical, Inc.
September 01, 2016 - N°20160250254

The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (esa) comprising administering soluble ferric triphosphate (sfp) composition and administering a dose of esa that is significantly reduced compared to the dose of esa required by a dialysis patient that is hyporesponsive to esa that has not received sfp.
Tissue protective peptides and uses thereof
Araim Pharmaceuticals, Inc.
August 25, 2016 - N°20160244498

The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including erythropoietin (epo), that are not involved in the binding of the ...
Isolated renal cells and uses thereof
Regenmedtx, Llc
July 21, 2016 - N°20160206659

The invention is directed to isolated renal cells, including tubular and erythropoietin (epo)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.
Loading